Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What is the possibility this company might be ultimately bought out along the way by a Johnson and Johnson or Merk type company? I took a look at there board of directors and they have a lot of experienced people including Mergers and Acquisition and IPO experience.
How close is SCS and Liberty to FDA aproval? Thank you for the information. I did some DD but could not figure out how close they are to FDA Approval.
A very difficult question to answer. SCS was the most publicize product in terms of where this company was regarding the approval needed from FDA. Now LIberty adds to the portfolio of products.
The market seems to be waiting for confirmation about these products technology in order to push the price further.
An announcement regarding SCS is probable soon. Once SCS proves merit most likely the price will surge again. Yet another finance announcement is also possible.
Personally $35 per share within the next two years is my expectation.
Any thoughts on how high $MBOT can go?
Just bought 328 shares of $MBOT. The worlds first fully disposable Robotic System for use in Neurovascular, Cardiovascular, and Pereipheral Systems and Endovascular procedures. Seems like long term Hold. Also Check out $SECI my other favorite technology hold.
* * $MBOT Video Chart 12-26-2019 * *
Link to Video - click here to watch the technical chart video
News: $MBOT Microbot Medical Inc. (NASDAQ:MBOT) Short Squeeze
Over the past twenty days of trading, Microbot Medical Inc. (NASDAQ: MBOT), from November 26, 2019 to December 24, 2019 there is a potential Short ...
Got this from MBOT - Microbot Medical Inc. (NASDAQ:MBOT) Short Squeeze
$MBOT must see Microbot Medical Inc Nasdaq Mbot Short Squeeze
Perfect also buying again
News: $MBOT Microbot Medical Inc. Announces $9.59 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
HINGHAM, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain ins...
In case you are interested MBOT - Microbot Medical Inc. Announces $9.59 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
The dilution is close to 20% of the total shares. The price correction is already ongoing.
The first milestone regarding SCS is yet to be announced, I expect it to be within the next 30 days.
HINGHAM, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 912,858 shares of its common stock, at a purchase price per share of $10.50, priced at-the-market under Nasdaq rules.
The closing of the offering is expected to occur on or about December 27, 2019, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately $9.59 million. Microbot currently intends to use the net proceeds from this offering for the continuous development and regulatory activities for its SCS device for the treatment of hydrocephalus and NPH; continue the development of the Company’s LIBERTY robotic system, including its expansion through addition of complementary assets to it either through internal development, in-license or acquisitions; expand and develop additional applications deriving from its existing IP portfolio, either through internal development, in-license or acquisition; and for working capital and other general corporate purposes.
The shares of common stock are being offered by Microbot pursuant to a “shelf” registration statement on Form S-3 that was originally filed on March 31, 2017 and declared effective by the Securities and Exchange Commission (“SEC”) on April 14, 2017 and the base prospectus contained therein (File No. 333-217076). The offering of the shares of common stock is being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying base prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Microbot Medical, Inc.
Microbot Medical Inc. (MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed with the SEC, which are or will be available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.
* * $MBOT Video Chart 12-24-2019 * *
Link to Video - click here to watch the technical chart video
I remembered that old saying about an hour ago, after the pu-erh tea kicked in: "Christmas Eve profit-taking is the better part of valor."
Or, something like that.
Happy Holidays, traders!
MBOT
Massive herd here playing adult musical chairs!
MBOT is nuckin’ futs. Congrats longs.........Merry
Christmas.
Sweet.....
Halt > Nasdaq circuit breaker!
This has turned out to be quite the Christmas present.....
Cash is partially restricted due to an ongoing dispute. 10 more months at the present burn rate is probable.
https://www.sec.gov/Archives/edgar/data/883975/000149315219017399/form10-q.htm#a_001
Although 4 million of that cash is set aside due to litigation with investment funds
They may not need to raise cash anytime soon for the following reasons.
They probably have around 8-9 million in cash at this time.
The financing they completed in Jan 2019 came with warrants that were exercisable at $10 with total value of $2.5 million.
Several potential news events could come at anytime, and with the presentation in Mid Jan in relation to news today share price should go much higher.
Strong after market price movement. 13.00 the price. We may have a new round of financing announcement as cash is needed in order to develop further the product portfolio.
A totally unexpected shift of events for me today, as I thought news to come would be related to another product, the SCS.
What is the real value of MBOT taking in consideration a successful SCS?
Maybe 1 B?
* * $MBOT Video Chart 12-23-2019 * *
Link to Video - click here to watch the technical chart video
News: $MBOT Microbot Medical to Unveil World's First Fully Disposable Robotic System for Endovascular Procedures
Live Demonstration Planned for Monday, January 13, 2020, in San Francisco Breakthrough technology features compact design, remote operation capabilities and an integrated “One & Done” tool to democratize endovascular procedures HINGHAM, Mass., Dec. 23, 2019 (GLO...
Read the whole news MBOT - Microbot Medical to Unveil World's First Fully Disposable Robotic System for Endovascular Procedures
It's about time the market woke up.....
Microbot Medical to Unveil World’s First Fully Disposable Robotic System for Endovascular Procedures
GlobeNewswire GlobeNewswire•December 23, 2019
Live Demonstration Planned for Monday, January 13, 2020, in San Francisco
Breakthrough technology features compact design, remote operation capabilities and an integrated “One & Done” tool to democratize endovascular procedures
HINGHAM, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) today announced the revealing of LIBERTYTM, the world’s first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular procedures. The LIBERTY robotic system features a unique compact design with the capability to be operated remotely, reduce radiation exposure and physical strain to the physician, as well as the potential to eliminate the use of multiple consumables through its “One & Done” capabilities. Microbot is set to publicly display and demonstrate LIBERTY to investors, journalists and healthcare industry leaders on Monday, January 13, 2020, in San Francisco.
“LIBERTY is set to revolutionize the way surgical robotics are being used in endovascular procedures, by eliminating the need for capital equipment, reducing radiation exposure and aiming to streamline the use of disposables during these complex procedures,” commented Harel Gadot, Chief Executive Officer, President, and Chairman. “In addition, with LIBERTY’s remote operation as well as its “One & Done” capabilities, we believe it has the potential to be the first system to democratize endovascular interventional procedures.”
LIBERTY is set to revolutionize the way surgical robotics are being used in endovascular procedures, by eliminating the need for capital equipment, reducing radiation exposure and aiming to streamline the use of disposables.
-Harel Gadot, CEO of Microbot.
Dr. Eyal Morag, an ABR certified Interventional Radiologist and Chairman of Radiology and Nuclear Medicine at Assuta Ashdod Medical Center in Israel, will be performing the live demonstrations highlighting the unique capabilities of LIBERTY.
“I believe LIBERTY will be welcomed by the interventional community due to its clinical and technical benefits in various subspecialties, such as neurovascular, cardiovascular and peripheral vascular interventions,” commented Dr. Morag. “The system set up is easy and straightforward, and it offers intuitive remote operation capabilities. These features are designed to reduce radiation exposure and eliminate physical strain on the physicians. Lastly, I believe it will democratize vascular procedures by shortening the physician’s learning curve.”
Unveiling/Demonstration Event & Webcast Video
To attend the LIBERTY unveiling and demonstration event on Monday, January 13, at 7:00 am PT, please contact Michael Polyviou at 732-933-2754 or mpolyviou@evcgroup.com.
Members of the media should contact Erich Sandoval at 212-867-1762 or erich.sandoval@finnpartners.com.
Monday, January 13, at 10:00 am ET
The full presentation of the unveiling and demonstration will be available and may be accessed in the ‘Investors’ section of the Company’s website at www.microbotmedical.com.
Additionally, the Company will be hosting One-on-One meetings in San Francisco on Monday, January 13, beginning at 9:00 am PT, through Wednesday, January 15, at 3:00 pm PT. To schedule a One-on-One meeting and a private demonstration, please contact Michael Polyviou at 732-933-2754 or mpolyviou@evcgroup.com.
Weakness most likely will continue. We may see the high 4s or low 5s levels again.
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Microbot Medical Inc.
Request to Withdraw Registration Statement on Form S-1
File No.: 333-228285
Ladies and Gentlemen:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Microbot Medical Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Company’s above-referenced Registration Statement on Form S-1 together with all exhibits and amendments thereto (collectively, the “Registration Statement”). The Registration Statement was initially filed with the Commission on November 8, 2018.
The Company is requesting to withdraw the Registration Statement because it does not intend to proceed with the planned registered offering of the securities covered under the Registration Statement at this time. The Registration Statement has not been declared effective by the Commission, and no securities were sold or will be sold under the Registration Statement. Therefore, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477 under the Securities Act.
The Company requests that, in accordance with Rule 457(p) promulgated under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.
Very truly yours,
Microbot Medical Inc.
By: /s/ Harel Gadot
Name: Harel Gadot
Title: CEO, President and Chairman
Not in this equity. GLTY.
So this is what they withdrew;
Up to 996,016 Shares of Common Stock
Up to 996,016 Pre-Funded Warrants to Purchase Shares of Common Stock and
996,016 Shares of Common Stock Underlying the Pre-Funded Warrants
We are offering up to 996,016 shares of our common stock.
We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable for one share of our common stock. The purchase price of each pre-funded warrant will be equal to the price per share at which shares of common stock are sold to the public in this offering, minus $0.01, and the exercise price of each pre-funded warrant will be $0.01 per share. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis.
Got a feeling we find out why pretty soon
*Microbot Medical Filing Shows Withdrawal Of Registration Statement On Form S-1
Benzinga
Good volume. After hours trading also important with a high of 8.24, ending at 7.50. Volume also high.
My expectation is that, a positive an important news will be released and soon after new financing agreements announced.
Hopefully above the price of 10.
Reducing dialysis shunt stenosis i.m.o could be even a greater driver than SCS. If SCS is success as I expect, the speed for developing other products will increase.
Very very large volume move today, not based on news to my knowledge. Maybe soon. If news are related to results we could see a continued price increase, but if related to a patent approval or similar, expect a pullback.
The pullback would mean that price settles again below 6 or even 5 in the short term.
As an example of previous price patterns, check price movements around announcements(Dialysis shunt stenosis news 24.7.19, Working prototype 05.09.19)
Breaking 10 will have to happen based on a powerful and important event as many shares were financed at that price.
* * $MBOT Video Chart 12-11-19 * *
Link to Video - click here to watch the technical chart video
MBOT moving up huge! > 8.30 up 27%.
Thank you. I have much to catch up on the business side here since I bought in on the technical indicators.
Microbot could yet again surpass 10 when news break. But, imo very very unlikely that the price will get to 20 even with news. MBOT continued solid results could make it a 150 stock. But in years time. Many trials, approvals and financing are needed. Are robots have multiple possible applications but need to prove merit.
Microbot could yet again surpass 10 when news break. But, imo very very unlikely that the price will get to 20 even with news. MBOT continued solid results could make it a 150 stock. But in years time. Many trials, approvals and financing are needed. Are robots have multiple possible applications but need to prove merit.
Microbot could yet again surpass 10 when news break. But, imo very very unlikely that the price will get to 20 even with news. MBOT continued solid results could make it a 150 stock. But in years time. Many trials, approvals and financing are needed. Are robots have multiple possible applications but need to prove merit.
I was a buyer last week when it appeared the price was breaking out of the large descending triangle on the weekly chart. This triangle has been the only deterrent for a position sooner due to the large gap at its base, and the possibility of filling it. The volume also tells me it may be about to blow again. I have a sense there is a lot of money on the sidelines waiting to pour in, and they are jumpy to not miss the rocket. Every large bid or big buy triggers a mini intraday squeeze/pop before a slow pullback.
Thanks for the resistance/pivot points. If we make our way to 20 and break it with news, the price could technically hit 35 based on the height of the triangle. I may add if the breakout is confirmed this week.
6.10, 7.40 and 10 are the prices that must be surpassed to provide very strong support.
Volume and price increasing. Possible behaviour in the stock price is that of july and september 2019, fast increase when the news is posted and then a decline. Also possible, another round of financing when news is released.
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1050
|
Created
|
11/29/16
|
Type
|
Free
|
Moderators |
Microbot Medical creates transformational micro-robotic medical technologies
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |